for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bioatla Inc

BCAB.OQ

Latest Trade

30.51USD

Change

-0.74(-2.37%)

Volume

60,504

Today's Range

30.26

 - 

31.27

52 Week Range

27.17

 - 

76.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
31.25
Open
30.84
Volume
60,504
3M AVG Volume
4.94
Today's High
31.27
Today's Low
30.26
52 Week High
76.58
52 Week Low
27.17
Shares Out (MIL)
33.81
Market Cap (MIL)
1,031.46
Forward P/E
-11.65
Dividend (Yield %)
--

Latest Developments

More

Bioatla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

Bioatla Posts Q1 Net Loss Of $18.7 Million

BioAtla Announces Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bioatla Inc

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. Its developing its second product candidate, BA3021, which is a CAB ADC targeting ROR2. Its third product candidate, BA3071, is a CAB anti-CTLA-4 antibody. The Company also uses its CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains.

Industry

Business Services

Contact Info

11085 Torreyana Road

SAN DIEGO, CA

92121

United States

+1.858.5580708

https://www.bioatla.com/

Executive Leadership

Jay M. Short

Chairman of the Board, Chief Executive Officer, Co-Founder

Scott A. Smith

President, Director

Richard Waldron

Chief Financial Officer, Senior Vice President

Christian Vasquez

Vice President - Finance, Corporate Controller, Company Secretary

Eric L. Sievers

Chief Medical Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-3.190

2021(E)

-2.683
Price To Earnings (TTM)
--
Price To Sales (TTM)
2,578.66
Price To Book (MRQ)
5.79
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.38
LT Debt To Equity (MRQ)
0.38
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up